Summary Epidermal growth factor receptors were measured using a radioligand binding assay in membrane preparations from 67 cancer and 25 non-malignant tissues.
Epidermal Growth Factor (EGF) is an important growth regulatory factor, that acts through a specific membrane receptor (EGFr) .
EGFr was extensively studied in breast cancer where it was expressed from 22% to 67% of cases (Koenders et al., 1991) and showed an inverse correlation with the estrogen receptors (ER) and the progesterone receptors (PR) in almost all the studies published to date. The clinical usefulness of EGFr is still under debate and its role in breast cancer has not yet been definitively established. EGFr mRNA and protein were also identified in non-malignant breast tissues. To date, few studies have investigated the distribution of EGFr in human non-malignant breast tissue. Using immunohistochemical methods, EGFr was found in normal epithelium and ducts (Damjanov et al., 1986) , and its expression was shown more frequently in non neoplastic than in cancer tissue (Moller et al., 1989; Tauchi et al., 1989; Tsutsumi et al., 1990) . The results obtained by ligand binding assay (LBA) methods are still conflicting (Barker et al., 1989; Ozawa et al., 1988; Pekonen et al., 1988) .
To evaluate the distribution of EGFr in breast tissue, this protein has been quantitatively determined both in cancer and in non-malignant tissues, and its concentration has been compared with steroid receptors.
Processing of breast tissue Tissue preparation was performed as previously described (Dittadi et al., 1990 We have correlated (Spearman rank correlation) EGFr with SR in the specimens evaluated. In non-malignant tissue a significant direct correlation between EGFr and both ER and PR was found (Figure 2 negative correlation was found between EGFr and both ER and PR (Figure 3) . A X2 analysis confirmed the inverse relationships between EGFr expression and both ER and PR in breast cancer (Table II) . EGFr was present in 92% of SR negative and in 48% of SR positive specimens (Figure 4 ).
Discussion
The These conflicting results may be due, not only to the small number of studies, but also to the differences and lack of standardisation between the binding assays used.
Using a standardised method according to the EORTC Receptor Study Group we found detectable high affinity EGFr in all non-malignant samples evaluated. In breast cancer specimens we found high affinity EGFr in less than 60% of cases. Moreover, in non-malignant specimens EGFr was directly correlated to both ER and PR, whereas in cancer tissue it showed an inverse relationship with steroid receptor, in agreement with the majority of published studies.
The finding of an opposite relationship between EGFr and steroid receptor in cancer with respect to non-malignant tissue confirm a trend previously indicated (Barker et al., 1989) . In particular, while almost all SR negative samples show detectable EGFr, 52% of SR + samples were EGFr negative.
We describe here, to our knowledge, for the first time, not only a more frequent but an unequivocally higher expression of EGFr in non-malignant samples than in cancer tissue. This finding emphasises the importance of sampling representative breast cancer tissue for EGFr assay since small quantities of non-malignant tissues may cause a severe overestimate of the EGFr level. The results suggest also that the possibility of a different role of EGF/EGFr loop should be investigated in SR + and SR -breast tumours.
